The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | ATOMIC: treating mesothelioma with an arginine-degrading enzyme and combination chemotherapy
Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, comments on the objectives and results of the ATOMIC (NCT02709512) clinical trial. This Phase II/III trial took advantage of the noticed vulnerability that non-epithelioid mesotheliomas have to arginine deprivation, and therefore studied the significance of using ADI-PEG 20, an arginine-degrading enzyme, with combination chemotherapy. The primary endpoints of PFS and OS were met. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy fees for RSOncology and Speaker bureau for BMS.
